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Peripheral Nerve Injury Associated with a Subdermal Contraceptive Implant: Illustrative
Cases and Systematic Review of Literature
Pierre Laumonerie1,2, Laurent Blasco3, Meagan E. Tibbo4, Olivier Leclair5, Panagiotis Kerezoudis4, Elodie Chantalat2,6,
Pierre Mansat1-BACKGROUND: Despite demonstrable safety and efficacy of subdermal
contraceptive implants (SCIs), both insertion and removal of SCIs in the arm have
been associated with neurovascular complications. The aim of this study was to
investigate type and prognosis of nerve injuries associated with SCIs.
-METHODS: We performed a comprehensive search of 4 electronic databases
for studies pertaining to patients with nerve injury and concurrent SCI. Studies
published between January 1987 and June 2017 were included. Implant location,
damaged nerves, clinical presentation, preoperative imaging (x-ray, ultrasound,
magnetic resonance imaging), neurologic evaluation (nerve conduction studies,
electromyography), and treatment methods were reviewed. To outline manage-
ment strategies, 2 illustrative cases of major nerve injury caused by SCI removal
were presented.
-RESULTS: We analyzed 10 studies including 12 patients. Fourteen nerve in-
juries in 12 patients were reported during SCI insertion (n 1) and removal
(n 11). Medial antebrachial cutaneous (n 5) and median (n 5) nerves
were primarily affected. Neuropathic pain was the main symptom. Primary
reasons for nerve injury were pulling or grasping of the nerve (n 9) after
mistaking it for the implant. Neurapraxia (n 7) was the most common lesion
and was treated with implant removal and clinical surveillance (n 6). Five
patients completely recovered; the remaining patients continued to have motor
and/or sensory deficit at mean follow-up of 0.7 year (range, 0 2 years).
-CONCLUSIONS: Nerve injuries related to SCIs are rare but potentially
serious. For nonpalpable SCIs, a multidisciplinary approach, including practi-
tioners with experience treating peripheral nerve injuries, is invaluable.
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Abbreviations and Acronyms
IO: Interossei
MABC: Medial antebrachial cutaneous
MRI: Magnetic resonance imaging
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Use of subdermal contraceptive implants
(SCIs) has been steadily increasing for
approximately a decade.1 The ﬁrst SCI
(Norplant; Wyeth-Ayerst International 
Inc., Wayne, Pennsylvania, USA) was
approved in 1983 and consisted of 6 rods 
placed subcutaneously into the medial
side of the nondominant arm. Norplant
was followed by a succession of innovative
SCIs, including 2-rod (Jadelle; Bayer 
Healthcare, Leverkusen, Germany, and
Sino-implant; Shanghai Dahua Pharma-
ceuticals Co., Shanghai, China) and
subsequently single-rod (Nexplanon and
Implanon; Merck, Darmstadt, Germany)
designs with a length of 40 mm and a
diameter of 2 mm. These innovationssigniﬁcantly reduced insertion andremoval time as well as complexity.
However, as procedural standardization
occurred, surgeons and obstetrician-
gynecologists became less and less
involved in the insertion of SCIs in favor of
general practitioners and midwives.2-6
Adverse events related to insertion,
localization, and removal of the SCI are
rare, affecting 1% of insertions and 1.7%
of removals, respectively.7 The
manufacturer of Nexplanon implants
estimates that intravascular placement
has occurred in just over 1 patient per 1
million Nexplanon implants sold.8
However, given the recommended site of
implantation, neurovascular injuries
remain a potential complication for both
SCI insertion and removal.9 In thisarticle, we present a systematic review of
the literature on nerve injuries associated
with SCIs. We also describe 2 patients at
our institution who sustained signiﬁcant
nerve injuries during removal of SCIs;
these serve as illustrative cases in an
effort to demonstrate our approach to
the treatment of these injuries. The
primary aim of this study was to
investigate the types of nerve injuries
associated with SCIs.MATERIALS AND METHODS
Illustrative Cases
Between 1983 and 2017, 2 patients with
serious nerve injuries resulting from SCI
Figure 1. Case 1. (A) Preoperative photograph depicting prior
incision (arrow) used to insert the subdermal contraceptive
implant into the medial aspect of the arm. (B) Intraoperative
image of the ulnar nerve (arrow). (C and D) Close up of the ulnar
nerve neuromas (arrow). UN, ulnar nerve.insertion were treated at our institution
(Médipôle de Koutio, Nouvelle-Calédonie,
France); their cases were retrospectively
reviewed. The SCIs were inserted at another
institution, and the patients were referred
to a peripheral nerve specialist (O.L.) in our
department to remove the device and treat
resulting nerve injuries. Records pertaining
to consultations, hospitalizations, and
surgical interventions in addition to labo-
ratory examination data (nerve conduction
studies and electromyography, ultrasound
[US], magnetic resonance imaging [MRI])
were reviewed for each case by an ortho-
paedic surgeon (P.L.) with experience in
peripheral nerve surgery.
Case 1. A 25-year-old womanwas referred to
our department after experiencing radiating
pain in the ulnar nerve distribution during
removal of an expired SCI (Figure 1). The
Implanon device was palpable on the
medial aspect of the arm and had been
removed under local anesthesia by a
midwife in clinic. Immediately
postoperatively, the patient was unable toﬁre the palmar and dorsal interossei (IO),
ﬂexor carpi ulnaris, or ﬂexor digitorum
profundus (fourth and ﬁfth digits)
muscles; she had a positive Froment sign
and grade S3 sensory loss over the ulnar
aspect of the palm (according to the British
Medical Research Council). The
aforementioned ﬁndings were initially
diagnosed by the treating physician and
subsequently conﬁrmed by a neurologist.
At 1 month, atrophy of IO and ﬂexible
ulnar claw posturing were also reported.
Electrophysiologic testing conﬁrmed a
severe sensorimotor ulnar neuropathy. The
ﬁrst dorsal IO and abductor digiti minimi
demonstrated 3þ ﬁbrillations without
activation. Sensory recordings were
signiﬁcant for persistence of
low-amplitude signals (25 mV). US
revealed fusiform enlargement of the ulnar
nerve fascicle as it coursed over the distal
third of the arm.
Owing to lack of improvement, surgical
exploration under general anesthesia was
performed 2 months later. The ulnar nerve
was in continuity with a 1-cm neuroma.No nerve action potential was recorded
across the lesion. Resection of the neu-
roma was performed to expose healthy
nerve tissue (1.5 cm); histologic examina-
tion later conﬁrmed the diagnosis of
neuroma. A 15-cm external neurolysis in
addition to subcutaneous transposition
were performed. The nerve was repaired
using a 10-0 nonabsorbable monoﬁlament
epiperineurial suture in an interrupted
fashion. At 12 months postoperatively,
extrinsic and intrinsic muscles had grade
M3 (British Medical Research Council)
strength, and ulnar clawing was dimin-
ished. Partial sensory recovery was ob-
tained (S3þ according to the British
Medical Research Council), but the pa-
tient’s ulnar paresthesias persisted.
Sequential postoperative electromyograms
documented reinnervation of ulnar nerve.
Case 2. A 31-year-oldwomanwas referred to
our department for a sensorimotor deﬁcit
occurring after failed removal of her SCI
(Figure 2). The procedure had been
performed in the operating room under
Figure 2. Case 2. (A) Preoperative photograph depicting
previous incision (arrow) over the subdermal contraceptive
implant on the medial aspect of the arm. (B) Intraoperative
photograph showing the subdermal contraceptive implant
(asterisk) in contact with the median nerve. (C and D) The ulnar
nerve after neuroma resection (arrow in C) at the time of implant
removal was treated with a sural nerve graft (arrow in D).
MN, median nerve; BA, brachial artery; UN, ulnar nerve.regional anesthesia by a gynecologist;
preoperative US did not allow for
identiﬁcation of the nonpalpable implant.
The gynecologist noted resistance after
pulling on a nerve rather than the
implant; the patient described at that
moment radiating pain in the ulnar nerve
distribution. At 1 month postoperatively,
weakness involving the IO, ﬂexor carpi
ulnaris, and ﬂexor digitorum profundus
(fourth and ﬁfth digits) was graded 2
(IO), 0 (ﬂexor carpi ulnaris), and 3 (ﬂexor
digitorum profundus). Flexible ulnar
clawing and Froment sign were noted.
The patient reported neuropathic pain
and grade S4 and S0 sensory loss
involving the fourth and ﬁfth digits,
respectively. At 6 months, atrophy of the
hypothenar eminence and all IO was
noted. Electrophysiologic testing
conﬁrmed a severe ulnar neuropathy
without signs of reinnervation. MRI
demonstrated fusiform enlargement of
the ulnar nerve fascicle in addition tomigration of the implant toward the
distal third of the medial arm.
Surgical exploration was performed 7
months later owing to lack of improvement
and necessity of implant removal. Preop-
erative US-guided hook-wire marking of
the implant was performed; this facilitated
removal of the nonpalpable implant. The
ulnar nerve had a 1.5-cm neuroma in
continuity at the site of putative injury. No
nerve action potential was recorded across
the lesion. The neuroma was resected to
expose healthy nerve tissue; subsequently,
interposition sural nerve grafting was
performed. Follow-up demonstrated
continued clinical improvement. By 11
months postoperatively, there was resolu-
tion of ulnar clawing and there were
improvements in both intrinsic and
extrinsic muscle strength (IO, grade 4;
ﬂexor carpi ulnaris, grade 5; ﬂexor dig-
itorum profundus fourth and ﬁfth digits,
grades 3 and 0). The patient also experi-
enced sensory recovery (S3þ in fourth digitand S3 in ﬁfth digit) and resolution of
neuropathic pain. Sequential postoperative
electromyograms demonstrated reinnerva-
tion changes in the ulnar nerve.
Literature Review
Literature Search Strategy. A literature
search was performed using Medical
Subject Headings and keywords in the
following databases: Ovid Medline, Ovid
Embase, Scopus, Web of Science, and
Cochrane. The search was limited to
English language literature; the terms
“peripheral nerve injury,” “contraception”
were combined with AND and OR. The
references in each study were reviewed to
identify additional articles corresponding
to the research criteria.
Selection Criteria. Articles included in the
present study were limited to articles that
discussed nerve injuries caused by SCIs
published between January 1988 and 2017.
Studies in a language other than English or
42 Records screened
gnineercS
ytilibigilE
27 Records excluded
Did not meet first step inclusion criteria
dedulcnI
Secondary screening by 2 independent reviewers with 
full-text articles
5   Number of studies and reasons for drop out :
2 Abstract of congress
2 Comment, letter to the editor
1 Radiological case report
10 Studies included in qualitative synthesis
15 Full-text articles assessed for eligibility
63 Clinical studies were identified from the following medical 
databases
0 Cochrane
15 Embase
18 Medline
23 Scopus
7 Web of Science
noitacifitnedI
42 Records selected after duplicates removed
0 Cochrane
9 Embase
18 Medline
14 Scopus
1 Web of science
10 Studies included in quantitative synthesis
Figure 3. Preferred Reporting Items for Systematic Reviews and
Meta Analyses flow chart summarizing search strategy for
relevant studies on peripheral nerve injuries caused by
subdermal contraceptive implants.
• 
• 
• • 
• 
l with inadequate design (meta-analysis, re-
view of the literature, abstract formeetings)
and studies centered exclusively on the
radiographic method of localization and/or
on removal techniques of nonpalpable
contraceptive implants were excluded.
Data Extraction and Critical Appraisal. Data
were extracted from article text, tables and
ﬁgures. Two investigators (P.L. and L.B.)
independently reviewed the full text of all
eligible articles. Disagreements between
the 2 reviewers were resolved via discus-
sion and consensus. When information
was incomplete, the corresponding au-
thors of the articles were contacted. Data
extracted from the articles included adescription of the nerve injuries, contra-
ceptive implants (model and location),
preoperative clinical and radiographic
presentation, surgical management, and
midterm to long-term clinical outcomes
following surgery. Level of evidence in the
included studies was assessed using the
criteria established by Oxford Centre for
Evidence-based Medicine Levels of
Evidence.10RESULTS
Quality of Studies
Our electronic search yielded 63 studies.
After applying inclusion and exclusioncriteria, 15 articles underwent full-text
evaluation. After detailed evaluation, 8
case reports (level of evidence V) and 2
case series (level of evidence IV) were
included in the analysis. A summary of the
search strategy is presented in Figure 3.
Population Characteristics
The cohort consisted of 12 patients with a
mean age of 29.8 years (range, 19e44
years) who were evaluated at a mean
follow-up of 0.7 year (range, 0e2 years); 1
patient was lost to follow-up.8 Norplanon
(n ¼ 4), Implanon (n ¼ 4), and
Nexplanon (n ¼ 4) SCIs were implanted
in the nondominant arm (8 left and 2
right; not available for 2 cases) either
Table 1. Patient Characteristics in 10 Articles Oescribing Peripheral Nerve Injuries Secondary to Subdermal Contraceptive Implants 
Published Between January 1988 and June 2017 
Age 
Study Country (years) 
Smith et al.. 199818 USA 
Sarma et al.. 199819 USA 
Marin and Mc:Millian. 19982° USA 
Nash and Staunton. 200121 United Kingdom 
Wechselberger et al.. 200616 Austria 
Gillies et al.. 2011 13 Australia 
Brown and Britton. 201212 United Kingdom 
Restrepo and Spinner. 201617 USA 
Belyea et al.. 201711 USA 
Odom et al.. 201714 USA 
NA, not available. 
23 
36 
17 
33 
24 
44 
26 
26 
19 
39 
36 
25 
Characterist ics 
Patients Subdermal Contraceptive Implant 
Upper Prior Removal Implant 
Limb Altempts Model lnserted by Site Depth Palpable 
Righi 0 Norplant Gynecologist Media! aspect of arm Subcutaneous Yes 
Left Norplant Gynecologist Media! aspect of arm Subfascial No 
Left Norplant Gynecologist Media! aspect of arm Subfascial No 
Left Norplant NA Media! aspect of arm Subcutaneous NA 
Left lmplanon Gynecologist Medial aspect of arm Subfascial No 
NA lmplanon General practitioner Media! aspect of arm Subcutaneous No 
NA lmplanon General practitioner Medial aspect of arm Subcutaneous No 
Righi 1 lmplanon NA 
Left 0 Nexplanon Gynecologist 
Left 2 Nexplanon Gynecologist 
Left 4 Nexplanon Gynecologist 
Left Nexplanon Gynecologist 
Media! aspect of arm Subcutaneous No 
Media! aspect of arm Subcutaneous No 
Media! aspect of arm Subfascial No 
Media! aspect of arm Subfascial No 
Media! aspect of arm Subfascial Yes subcutaneously (n = 6) or beneath the 
fuscia (n = 6). The implants were not 
palpable in 7 patients; tbis information 
was not available for 1 case. Ali patients 
had an abnormal clinical examination or 
additional study findings. Neuropathie 
pain (n = 12) was identified in all 
patients. Clinical examination revealed 
paresthesias in u patients, weakness in 6 
patients, and sensory Joss in 8 patients. 
Electrodiagnostic studies were performed 
in symptomatic patients (n = 4) either 
before or after device removal. 
Ultrasound images (n = 8) and/or 
radiographs (n = 2) were sufficient to 
localize the implant in 7 patients8•11• 16 
and, later, to better describe the nerve 
injury in 1 patient. 17 No patient 
underwent preoperative MRL Population 
characteristics are reported in Tables 1 
and 2. 
Peripheral Nerve Injuries 
There were 14 peripheral nerve IIlJlmes 
associated with SCis reported during or 
after insertion (n = 2) and removal 
(n = 12) procedures; no associated Jesions were reported. The 2 most co=only 
injured nerves were the medial ante-
brachial cutaneous (MABC) nerve (n = 5) 
and median nerve (n = 5). Nerve injury 
was primarily due to pulling or grasping of 
the nerve (n = 9) after mistaking it for the 
implant. Neurapraxia (n = 7) was the most 
co=on Jesion and was treated primarily 
with implant removal and clinical surveil-
lance (n = 6). Nerve coaptation (n = 2) 
was performed for partial nerve transec-
tion. N eurolysis ( extemal neurolysis 
[ n = 1] or epineurolysis [ n = 1]) was 
performed to treat neuroma or nerve 
compression by scar tissues and/or SCis. 
Of patients, 5 completely recovered, and 6 
continued to have a motor and/or sensory 
deficit at short-term to Jong-term follow-
up; 1 patient was Jost to follow-up.' 9 No 
additional interventions were performed 
for the treatrnent of seq uelae. 
Management by a pain specialist was 
requested in 1 case owing to persistent 
dysesthesia and paresthesia in the band 
4 months after coaptation of the median 
nerve. 22 The results are summarized in 
Table 2. DISCUSSION 
Difficulties encountered during the 
removal ofSCis have stimulated intensive 
research into the development of easy-to-
use systems.9•23 The development of 
these new devices will Iikely reduce the 
incidence of insertion site complica-
tions. 9•24•25 Although rare, SCis have the 
potential to cause serious peripheral nerve 
m1ur1es during insertion and 
removal.11•14•17 The broader, more corn-
mon spectrurn of adverse implant site re-
actions include pain, hematoma, swelling, 
redness, and scarring.4•26 These compli-
cations were described in 5.9°/o of women 
within the first few years after SCI inser-
tion and/or removal. 27 The insertion 
procedure is straightforward and can 
typically be performed in the office. 
Implants must be inserted into the 
subcutaneous space on the medial aspect 
of the nondominant arm 8-10 cm 
proximal to the medial epicondyle under 
local anesthesia via a disposable sterile 
applicator. The SCI must be palpable 
throughout the duration of its use.'5.23 
After a maximum of 3 years, the palpable
implant is removed under local
anesthesia through a small incision at
the distal end of the rod. Manual
pressure is applied to the proximal end
of the device to push it through the
2-mm incision and grasp it with forceps
as it appears; no dissection is
required.4,5,15,28,29
In the medial aspect of the midarm,
neurovascular structures are separated
from one another by the brachialis fascia
that divides the arm into superﬁcial and
deep compartments. The MABC nerve lies
within the subcutaneous space along with
the basilic vein.16 The MABC nerve courses
within the anterior proximal arm, medial
to the brachial artery; it becomes a
subcutaneous structure when it pierces
the brachial fascia (basilica hiatus) 14 cm
proximal to the medial epicondyle. SCIs
are typically inserted in this vicinity;
therefore, it follows that incorrect
subcutaneous positioning of the implant
may induce damage to the branches of
the MABC nerve (anterior, or ulnar).16,30
The subaponeurotic course of the MABC
nerve also places it at risk for injury
owing to accidental traction at the time
of implant removal. The spectrum of
injuries to the MABC nerve described in
the literature is broad, ranging from
neurapraxia to complete nerve
transection (Table 2). Clinical symptoms
are also variable and may include
impaired sensation. An area of localized,
severe pain in the distribution of the
MABC nerve may occur in the case of a
transected nerve trapped in scar tissue.16
Neurovascular structures beneath the
fascia are also at risk; these structures
include the brachial artery and terminal
branches of brachial plexus (Figures 1
and 2, Table 2). Accidental traction on
the nerve rather than the implant at the
time of removal and nerve compression
are the 2 primary reasons for incomplete
injuries. Nerve transection (n ¼ 6) is the
second most common injury pattern and
affecting the median and/or ulnar nerves
overall; emergent surgical treatment
should be the rule in this setting because
of the risk of neuroma formation
(Figures 1 and 2, Table 2).
Although previous reports quote
migration rates reaching 39%,31 a recently
published study of 4294 practitioners
demonstrated migration in only 0.26% ofcases,2 with most implants migrating<2 cm
from the initial insertion site. Too-deep
initial positioning and/or migration of
the implant may lead to difﬁculty with
localization via palpation at the time of
implant removal. In our study, 83% of
nerve injuries involved patients with non-
palpable implants. A standardized clinical
and radiographic evaluation should be
undertaken to locate the nonpalpable SCI,
the neurovascular structures, and possible
associated lesions to facilitate safe implant
removal.14,24 Neurovascular sequelae
resulting from insertion or removal of a
SCI must be identiﬁed at the time of initial
evaluation for patients requesting a new
device. Scarring induced by a malposi-
tioned implant can also place pressure on
the nerve at a distance from the SCI
insertion site.20,21 Clinical assessment
should include a detailed history to accu-
rately understand the patient’s symptoms
as well as attempted implant palpation;
this provides an initial impression
regarding the location of possible nerve
injuries. Neuropathic pain at the level of
the upper arm or a history of SCI use
should prompt the physician to suspect
nerve injury. Any loss of distal sensory and
motor function associated with insertion
or removal of an SCI should be treated as a
suspected serious nerve injury and
addressed within days (Table 2); any delay
in treatment exposes patients to the risk of
neuroma formation (Figure 1C).17 Recent
literature describes the use of various
methods to localize nonpalpable SCIs,
including x-rays, US, computed
tomography, and MRI.1,14,20,24,26,32-36 US
examination should be considered the
ﬁrst-line imaging because of its low cost,
lack of ionizing radiation, and wide avail-
ability.24,37 MRI is the best method for
unequivocal localization of implants not
detectable on US.24,35,37 High-resolution
3T MRI with T1-weighted, T2-weighted,
or gradient echo sequences (spoiled
gradient recalled echo) with robust fat
suppression, with and without gadolinium
enhancement is the recommended
second-line imaging for implant localiza-
tion and peripheral nerve imaging.24,37
Despite the fact that US was used in 75%
of patients in this study, no diagnostic
MRI studies have been reported in the
literature. In cases where intraoperative
implant localization is challenging,
extensive dissection must be avoided. Werecommend intraoperative US-guided
hook-wire marking of the implant by an
experienced musculoskeletal radiologist to
facilitate safe dissection.38 For
symptomatic patients, nerve conduction
studies and electromyography can assist
further by determining the severity of the
injury and conﬁrming its location; these
studies also allow for improved clinical
follow-up of patients in whom lesions
are treated with or without surgery.
All nerve injuries that occurred during
the removal of nonpalpable SCIs were
caused by providers without formal micro-
surgical training (Table 2). Given the risks
of neurovascular injury with nonpalpable
SCIs, we recommend asking a peripheral
nerve specialist for assistance with
removal.14,24 In the event that an
inadvertent nerve injury is suspected,
immediate action should be undertaken.
We avoid local anesthetics and paralytics,
as they preclude intraoperative nerve
stimulation. In the present study, 75% of
nerve injuries were associated with
accidental traction (pulling or grasping)
on the nerve when it was mistaken for
the SCI. For this reason, we advocate for
wide operative exposure, avoiding
grasping the nonpalpable implant with
surgical instruments until it has been
identiﬁed in its entirety and separated
from adjoining tissues (Figure 1, Tables 1
and 2).17 For patients with clinical or
electromyographic evidence of nerve
injury, the nerves in close proximity to the
implant must be exposed and inspected.
A nerve stimulator (Vari-Stim III Nerve
Locator; Medtronic Xomed, Inc.,
Jacksonville, Florida, USA) is needed to
identify abnormally functioning nerves in
cases where no striking visual abnormality
is present intraoperatively. When
complete nerve transection is
encountered, timely surgical repair should
be performed using 9-0 or 10-0 epineural
nonabsorbable monoﬁlament suture
placed in an interrupted fashion under
direct visualization with surgical loupes or
a microscope.32 When direct repair is not
feasible, a graft must be used (Figure 1).
Neurotization and/or tendon transfer
should be considered for proximal nerve
transections with motor deﬁcits lasting
>6 months.22,32,39 In the case of
superﬁcial lesions, if primary nerve
coaptation of the MABC nerve is not
possible, its proximal end should be
Table 2. Summary of Various Treatment Approaches in 10 Articles Describing Neurovascular Complications After Subdermal Contraceptive Implant Insertion and/or 
Removal Published Between January 1988 and June 2017 
Nerve lnjury Treatment 
Times to 
Nerves Mecbanism Treating Treatment Treating Functional 
Study lnvolved Lesion Tuning of lnjury Provider Treatment (montbs) Provider Outcomes 
Smith et al., 199818 Ulnar Contusion by needle Rernoval Nerva contusion Gyneœlogist Clin.::al and Neurologist Residual deficit 
("U" technique)9 physiolog.: 
surveillance 
Sarrna et al., 199819 Median Neurapraxia Second rernoval Pulling/grasping on Gyneœlogist Implant rernoval and lnterventional Lost to follow up 
attempt nerve clinical surveillance radiologist 
Marin and Ulnar Neurapraxia After removal Compression by scar Gyneœlogist Epineurolysis NA Residual deficit 
McMillian, 19982° tissues 
Nash and Staunton, MABC Neurapraxia After insertion Compression by NA Implant rernoval and NA Residual deficit 
2001 21 implant clin.:al and 
and/or scar tissues physiolog.: 
surveillance 
Wechselberger MABC Partial section Attempted removal Pulling/grasping on Gyneœlogist Implant rernoval and NA Piast.: surgeon Fu Il recovery 
et al., 200616 nerve nerve coaptation 
Gillies et al., 201113 Median Partial section Attempted removal Pulling/grasping on Gyneœlogist Implant rernoval and 0.4 (12 days) Hand surgeon Residual deficit 
nerve nerve coaptation 
Median Partial section Attempted removal Pulling/grasping on Gyneœlogist Implant rernoval and 0.03 (1 day) Hand surgeon Residual deficit 
nerve nerve coaptation 
Brown and Britton, MABC Neurapraxia Insertion Compression by NA Implant rernoval and 24 Orthopaed.: Fu Il recovery 
201212 implant clinical surveillance surgeon (imrnediate 
postprocedure) 
Restrepo and MABC, median, Sections (n 3) Rernoval Pulling/grasping on Gyneœlogist External neu rolysis 5 Neurosurgeon Full recovery (ulnar 
Spinner, 201617 and ulnar compl.::ated nerve (median, ulnar, and nerve); residual 
by neurornas (n 3) MABC) deficit (MABC, 
rnedian nerves) 
Belyea et al., 201 ]11 Median nerve Neurapraxia Second rernoval Pulling/grasping on Gyneœlogist Implant rernoval and NA Orthopa ed.: Full recovery 
attempt nerve clinical surveillance surgeon 
Odom et al., 201 l14 NA Neurapraxia Fourth rernoval Pulling/grasping on Gyneœlogist Implant rernoval and NA Piast.: surgeon Fu Il recovery 
attempt nerve clinical surveillance 
MABC Neurapraxia Removal attempt Pulling/grasping on Gyneœlogist Implant rernoval and 0.1 (3 days) Piast.: surgeon Fu Il recovery 
nerve and/or clinical surveillance 
compression by 
implant 
NA. not available; MMC, medial anteb'adlial cutaneous. 
transposed proximally and buried deep into
the muscle of the arm to avoid formation of
a painful neuroma.16,40
Limitations
The limitations of this study relate to its
retrospective, single-center nature and
sample size. The retrospective design
inherently leads to more loss of data and
bias. Owing to the small number of cases
and the nature of this study, speciﬁc rec-
ommendations for surgical treatment
cannot be established. Follow-up was of
short duration for most patients (mean 0.7
year; range, 0e2 years), and neurologic
data were sparse; this did not allow for a
reliable analysis of postoperative outcomes
after treatment of these injuries.
Lessons Learned
All patients with nonpalpable SCIs are at
risk for serious nerve injury and require a
thorough preoperative imaging evaluation
and referral to a peripheral nerve specialist.
Neuropathic arm pain in a patient with an
SCI should prompt the clinician to suspect
a nerve injury until proven otherwise. In the
setting of deep, nonpalpable implants, a
large incision that sufﬁciently exposes the
entirety of the SCI is advised to avoid acci-
dental injury to neighboring neurovascular
structures. A handheld electrical stimulator
may also be useful in cases where nerve
injury is suspected.
Future Directions
To further improve on the safety of con-
traceptive implants, we should consider
revising the recommended area of im-
plantation provided by manufacturer (a
minimum of 8 cm above the medial epi-
condyle) to avoid vulnerable nerves and
vessels of the medial arm.14 Placement over
the body of the biceps brachii or into the
medial thigh are possible alternatives, but
both may be cosmetically
unappealing.19,41 Wechselberger et al.16
speculated that Implanon insertion into
the medial supraumbilical region through
the umbilicus might be an ideal way to
prevent scarring and eliminate the risk of
neurovascular injury. Both etonogestrel
contraceptive implants are off-white and
visually similar to nerves and blood vessels.
We advocate changing the color of the de-
vice to the green or turquoise used during
the manufacturer training programs
required by the U.S. Food and DrugAdministration to avoid confusion at the
time of implant removal.14
CONCLUSIONS
Nerve injuries related to SCIs are rare but
serious. In cases of nonpalpable implants, a
multidisciplinary approach including prac-
titioners with expertise in the treatment of
peripheral nerve lesions is invaluable.
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